Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02)

被引：0

作者：

Oh, Do-Youn

Lugowska, Iwona A.

Stroyakovskiy, Daniil

Jung, Kyung Hae

Dumas, Olivier

Penkov, Konstantin

Dechaphunkul, Arunee

Oaknin, Ana

Kim, Seung Tae

Starling, Naureen

Chewaskulyong, Busyamas

Charonpongsuntorn, Chanchai

Doroshow, Deborah Blythe

Hsiao, Sheng-Yen

Hung, Yi-Ping

Jung, Lindsey

Kuptsova-Clarkson, Nataliya

Michelini, Flavia

Puvvada, Soham D.

Meric-Bernstam, Funda

机构：

[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[2] Maria Sklodowska Curie Natl Res Inst & Oncol Ctr, Early Phase Clin Trials Dept, Warsaw, Poland

[3] Moscow City Oncol Hosp 62, Moscow, Russia

[4] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea

[5] Hotel Dieu Quebec, Quebec City, PQ, Canada

[6] Clin Hosp RZHD Med, St Petersburg, Russia

[7] Prince Songkla Univ, Dept Med, Med Oncol Unit, Fac Med, Hat Yai, Thailand

[8] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol, Gynaecol Canc Programme, Barcelona, Spain

[9] Samsung Med Ctr, Seoul, South Korea

[10] Royal Marsden NHS Fdn Trust, Gastrointestinal Unit, London, England

[11] Inst Canc Res, London, England

[12] Chiang Mai Univ, Chiang Mai, Thailand

[13] Srinakharinwirot Univ, Dept Internal Med, Med Oncol Unit, Fac Med, Nakhon Nayok, Thailand

[14] Icahn Sch Med Mt Sinai, New York, NY USA

[15] Chi Mei Med Ctr, Div Hematol Oncol, Dept Internal Med, Tainan, Taiwan

[16] Taipei Vet Gen Hosp, Taipei, Taiwan

[17] AstraZeneca, Gaithersburg, MD USA

[18] AstraZeneca, Oncol R&D, Gaithersburg, MD USA

[19] AstraZeneca, Translat Med, Oncol R&D, Waltham, MA USA

[20] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4090

引用

页数：1

共 50 条

[21] An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01,-02, and-03
Krop, Ian E.
Wildiers, Hans
Hurvitz, Sara A.
Cortes, Javier
Im, Seock-Ah
Iwata, Hiroji
Andre, Fabrice
Saura, Cristina
Modi, Shanu
Kim, Sung-Bae
Egorov, Anton
Mathias, Elton
Cathcart, Jillian
Cagnazzo, Antonio
Cheng, Yingkai
Park, Yeon Hee
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[22] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
Raghav, Kanwal Pratap Singh
Siena, Salvatore
Takashima, Atsuo
Kato, Takeshi
Van den Eynde, Marc
Di Bartolomeo, Maria
Komatsu, Yoshito
Kawakami, Hisato
Peeters, Marc
Andre, Thierry
Lonardi, Sara
Yamaguchi, Kensei
Tie, Jeanne
Castro, Cristina Gravalos
Strickler, John H.
Barrios, Daniel
Yan, Qi
Kamio, Takahiro
Kobayashi, Kojiro
Yoshino, Takayuki
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[23] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
Siena, Salvatore
Di Bartolomeo, Maria
Raghav, Kanwal Pratap Singh
Masuishi, Toshiki
Loupakis, Fotios
Kawakami, Hisato
Yamaguchi, Kensei
Nishina, Tomohiro
Fakih, Marwan
Elez, Elena
Rodriguez, Javier
Ciardiello, Fortunato
Saxena, Kapil
Yamamoto, Eriko
Bako, Emarjola
Okuda, Yasuyuki
Shahidi, Javad
Grothey, Axel
Yoshino, Takayuki
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01,-02, and-03
Hurvitz, S. A.
Modi, S.
Li, W.
Park, Y. H.
Chung, W.
Kim, S-B.
Cortes, J.
Yamashita, T.
Pedrini, J.
Im, S-A.
Tseng, L-M.
Harbeck, N.
Krop, I.
Curigliano, G.
Mathias, E.
Cathcart, J.
Cagnazzo, A.
Ashfaque, S.
Egorov, A.
Andre, F.
ANNALS OF ONCOLOGY, 2023, 34 : S335 - S336
[25] Circulating tumor DNA (ctDNA) analyses in patients with HER2-positive biliary tract cancer (BTC) treated with trastuzumab deruxtecan (T-DXd): Exploratory results from the HERB trial
Ohba, Akihiro
Morizane, Chigusa
Kawamoto, Yasuyuki
Komatsu, Yoshito
Ueno, Makoto
Kobayashi, Satoshi
Ikeda, Masafumi
Sasaki, Mitsuhito
Furuse, Junji
Okano, Naohiro
Hiraoka, Nobuyoshi
Yoshida, Hiroshi
Kuchiba, Aya
Sadachi, Ryo
Nakamura, Kenichi
Matsui, Naoko
Nakamura, Yoshiaki
Okamoto, Wataru
Yoshino, Takayuki
Okusaka, Takuji
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[26] Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.
Janne, Pasi A.
Goto, Yasushi
Kubo, Toshio
Ninomiya, Kiichiro
Kim, Sang-We
Planchard, David
Ahn, Myung-Ju
Smit, Egbert F.
De langen, Adrianus Johannes
Perol, Maurice
Pons-Tostivint, Elvire
Novello, Silvia
Hayashi, Hidetoshi
Shimizu, Junichi
Kim, Dong-Wan
Pereira, Kaline
Cheng, Fu-Chih
Taguchi, Ayumi
Cheng, Yingkai
Goto, Koichi
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[27] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)
Smit, E. F. F.
Li, B. T.
Mazieres, J.
Planchard, D.
Nakagawa, K.
Goto, K.
Paz-Ares, L.
Novello, S.
Yang, J. C-H.
Ahn, M-J.
Liu, G.
O'Byrne, K.
Aregay, M.
Shiga, R.
Saxena, K.
Meinhardt, G.
Janne, P. A.
ANNALS OF ONCOLOGY, 2021, 32 : S1032 - S1033
[28] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)
Yoshino, Takayuki
Di Bartolomeo, Maria
Raghav, Kanwal Pratap Singh
Masuishi, Toshiki
Kawakami, Hisato
Yamaguchi, Kensei
Nishina, Tomohiro
Wainberg, Zev A.
Elez, Elena
Rodriguez, Javier
Fakih, Marwan
Ciardiello, Fortunato
Saxena, Kapil
Kobayashi, Kojiro
Bako, Emarjola
Okuda, Yasuyuki
Meinhardt, Gerold
Grothey, Axel
Siena, Salvatore
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[29] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
Yoshino, Takayuki
Di Bartolomeo, Maria
Raghav, Kanwal Pratap Singh
Masuishi, Toshiki
Loupakis, Fotios
Kawakami, Hisato
Yamaguchi, Kensei
Nishina, Tomohiro
Wainberg, Zev A.
Elez, Elena
Rodriguez, Javier
Fakih, Marwan
Ciardiello, Fortunato
Saxena, Kapil
Kobayashi, Kojiro
Bako, Emarjola
Okuda, Yasuyuki
Meinhardt, Gerold
Grothey, Axel
Siena, Salvatore
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[30] Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells.
Yu, Seo Young
Park, Juin
Kwon, Woo Sun
Jeong, Inhye
Kang, Sun Kyoung
Bae, Hyun Joo
Kim, Tae Soo
Chung, Hyun Cheol
Rha, Sun Young
CANCER RESEARCH, 2021, 81 (13)

← 1 2 3 4 5 →